The first time you hear a billionaire joke, half-serious, about “aging being a disease we’ll cure,” it sounds almost charming—like science fiction slipping into real life. You picture sleek labs, glowing tanks, a gray-haired patient standing up from a hospital bed with tears in their eyes as the wrinkles smooth away. It feels hopeful. Then, if you’re unlucky enough to hear the rest of the sentence, the charm curdles. Because sometimes the sentence ends with something like: “And once we cure aging, we’ll have to rethink who gets to live—and how long.”
The Private Conversations Behind the Public Utopia
In public, the story is simple: tech titans pouring money into curing disease, extending healthy life, “democratizing longevity” for everyone. It’s the TED Talk dream—sleek slides, big fonts, a final line about “a future where your children can live to 150 in perfect health.” People clap. Articles gush. Stock prices twitch.
But step away from the stage lights and into the back rooms—off-record dinners, off-site retreats, NDA-heavy “health summits”—and you hear a different song, a quieter one, more precise, with notes that don’t quite resolve.
An insider who has worked with multiple longevity-startup founders described it this way: “In the slide decks, they talk about ending suffering. In the private strategy meetings, they talk about allocating scarce immortality. Seriously—that’s the phrase. Who gets it first. Who is ‘worth’ it. How to ‘align public policy’ so the rollout doesn’t provoke riots.”
“Worth it,” in these circles, is not a moral concept. It is a metric.
Metrics, Models, and the Quiet Devaluation of Human Beings
To understand how we get from “cure aging” to “who deserves to live longer,” you have to step into the mind of a Silicon Valley optimizer. For these people, life is a system, society is a machine, and human beings are units in a model—nodes in a giant, constantly updating spreadsheet.
In that spreadsheet, every node has variables: age, health status, productivity, predicted lifespan, cost of care, economic output, and maybe a score for “innovation potential.” In closed-door meetings, according to leaked decks and those who have sat through them, these variables produce a crude, brutal number: a lifetime “value” score.
Above a certain number, the node—meaning the person—is a candidate for aggressive longevity interventions. Below that number, they slide silently into the category that one executive reportedly called “status quo mortality.” A tidy phrase to mean: we don’t actively kill you; we simply don’t save you.
The New Eugenics Is Dressed in Clean White Fonts
There is an old word for ranking human lives by worth and steering resources accordingly: eugenics. We think we buried that word in the last century, under the weight of camps and experiments and unspeakable horror.
But eugenics doesn’t always return in black boots. Sometimes it comes back in DTC genetic testing kits and lifestyle apps that recommend “optimized mating choices.” Sometimes it arrives in corporate slide decks titled “Strategic Allocation of Regenerative Therapies in High-Impact Populations.” Sometimes it walks onstage in a black turtleneck and tells you, smiling broadly, that “the best way to help the poor is to ensure the rich stay innovative long enough to solve humanity’s problems.”
An executive at a “longevity fund” once described to a consultant how they prioritized investments: “We’re not in the business of adding five years to a 90-year-old in a nursing home. We’re in the business of adding 40 hyper-creative years to a 45-year-old founder.” No one around the table objected. They nodded, took notes, adjusted projections.
In the sanitized language of venture capital, some lives are “force multipliers.” Others are “cost centers.” Once you accept that logic, everything else follows unnervingly smoothly.
Medicine as a Gate, Not a Gift
It’s easy to assume that healthcare is guided by doctors and public health officials. But in the last decade, a growing share of the frontier—gene editing, organ regeneration, AI diagnostics, anti-aging therapies—has quietly shifted into private, billionaire-funded labs. The incentives changed with the funding source.
Inside these labs, medicine is starting to look less like a right and more like a privilege—an upgrade, a premium subscription, a feature you unlock if you have the right status, genetics, or bank account. What begins as “early access for those who can pay” slowly hardens into “standard access for those who matter.”
A physician who briefly consulted for a high-end “longevity clinic” in California described the intake process: extensive genetic panels, biomarkers, behavioral data imported from wearables, psychological profiling. “They weren’t just treating patients,” she said. “They were ranking them. There was a clear sense that some profiles were ‘ideal investments’ and others were nice PR stories at best.”
Behind the scenes, internal documents discussed “therapeutic tiers”: basic, advanced, elite experimental. Getting into the highest tier meant more than just money; it meant having the “right” combination of youth, health, estimated remaining productive years, and social influence. A tech CEO with a hundred employees might be prioritized over a retired teacher with three grandchildren—because the model says one can “change the world” and the other has “closed their productive chapter.”
Table: How an Optimizer Might Quietly Rank Who Gets Life-Extending Care
| Profile | Age | Health Status | Economic/Influence Score | Modeled “Return” on Extra 30 Years | Access Priority (Insider Models) |
|---|---|---|---|---|---|
| Unicorn Founder | 42 | Excellent | Very High | Multiple new companies, patents, GDP growth | Top-tier, early experimental access |
| AI Researcher | 38 | Good | High | Advances in automation, defense, data control | High priority |
| Nurse, Single Parent | 52 | Moderate (chronic issues) | Medium | Community stability, family support | Standard care, limited advanced options |
| Retired Factory Worker | 74 | Poor | Low | Minimal projected economic return | Low priority, “status quo mortality” |
| Disabled Activist | 30 | Variable | Social but not financial | Non-economic impact, system-critical dissent | Unmodeled, often deprioritized |
No one will ever hand you a table like this in real life. Yet, versions of it exist in spreadsheets, models, and slide decks—shaping which diseases get funded, which trials get fast-tracked, which populations are studied, and which are quietly ignored.
Housing the “Useful,” Displacing the Rest
Immortality, or anything near it, has a simple spatial problem: bodies take up space. If people at the top live longer, in better health, still working and accumulating wealth deep into what used to be “old age,” where do they live? And what happens to everyone else?
Look closely at the “smart city” projects, billionaire-built enclaves, and quasi-private company towns cropping up around the world. On the surface, they’re about sustainability, walkability, climate resilience, innovation. Underneath, critics see something else: a real estate strategy for a stratified future.
One urban planner who reviewed confidential materials for a proposed “innovation city” described an internal segmentation of residents based on their “long-term productivity curve.” The highest tier: “founders, researchers, key talent.” Below that: “service professionals.” At the bottom: “transient dependency groups”—a cold phrase encompassing the elderly poor, chronically ill, disabled, and those judged “unlikely to contribute to the innovation ecosystem.”
Public renderings of the project showed parks, tech hubs, sleek co-living spaces, children playing in spotless plazas. Missing from the pictures were nursing homes, public housing, shelters, or anything visibly associated with decline, frailty, or human messiness. Those, according to draft zoning notes, would be “managed through regional partnerships”—a polite way of saying: kept outside the walls.
When Policy Starts to Whisper, “Maybe They Shouldn’t Be Here”
Most of us won’t ever sit in a longevity lab, but we do live inside the policies being quietly shaped by those who fund them. The influence is subtle: white papers, endowed chairs, “advisory councils,” think tanks with names that sound like they’re just trying to help humanity be smarter and safer.
Inside those documents are recurring themes. Encouraging “healthy aging” sounds benign—until it becomes a pretext for cutting support to those who age in ways the models don’t like. Promoting “active contribution across the lifespan” seems harmless—until “inactive” lives are framed as burdens on the hyper-productive core.
It’s not just health. Housing policies begin to favor “dynamic, innovation-driven residents.” Education systems pivot resources toward “high-impact talent pipelines.” Insurance nudges people with subtle punishments for being old, sick, or non-compliant with optimization metrics. The story beneath the policies is always the same: certain kinds of humans are future-makers; others are merely future-costs.
One policy strategist described a private session with tech leaders this way: “They kept returning to the same phrase: ‘societal ROI.’ Who do we keep alive, comfortable, and present in our shared spaces, and who do we manage quietly at the edges. It was like listening to software engineers talk about garbage collection in memory management, except they meant people.”
The Defenders, the Alarm Bells, and the Battle Over the Story
Speak these concerns out loud, and you will be met with fury from defenders of the billionaire class. They will tell you that without these men—and they are mostly men—we’d have no mRNA vaccines, no AI-assisted diagnostics, no rush toward cures for cancer, Alzheimer’s, Parkinson’s. They will argue that, yes, the rich will benefit first, but that’s how innovation works: expensive at the top, then cheaper for everyone else.
Some of this is even true. Many of the same people flirting with a eugenic logic of “high-value lives” are also bankrolling breakthroughs that genuinely save millions. That duality is what makes this moment so disorienting. The line between savior and architect of dystopia is not a clean, cinematic division. It runs right through the same human beings, the same companies, sometimes the same projects.
Critics, meanwhile, warn that the “it will trickle down” story has already failed in housing, wages, and basic healthcare. They see no reason to expect immortality or advanced gene therapies to be any different. When a therapy can add decades of youth to a billionaire, does anyone truly believe it will be priced or regulated to reach a grocery clerk?
Bioethicists raise another, more chilling fear: that once a class of “engineered elites” exists—longer-lived, cognitively enhanced, genetically fine-tuned—the political will to extend those benefits to everyone else may vanish. Why would the optimized voluntarily erode the gap that justifies their power?
A Future We Never Voted For
Democracy is supposed to give us a say in the shape of our collective future. But almost no one has ever been asked, in any election, whether we want to live in a world where some people can buy decades of extra life while others die on schedule. We haven’t debated, as a public, the ethics of editing embryos for intelligence, or of restricting life-extending therapies to the “high performing.”
Instead, those decisions are being made in boardrooms, labs, and private gatherings in mountain resorts—by people who can spend more on a weekend health retreat than many families see in a year. They are not cartoon villains. They are brilliant, driven, often sincerely convinced they are steering humanity toward a better world.
But their better world is optimised for a very particular kind of human: the tireless innovator, the data-fueled striver, the person whose usefulness can be quantified in code and capital. Everyone else is gently edged out of the frame—first from the renderings, then from the neighborhoods, then from the funding models, and finally from the medicine that decides who stays and who goes.
This is the unpalatable reality beneath the glossy promises of immortality: not that some people might live longer, but that our collective sense of whose life is worth living may be quietly rewritten to fit the preferences of those who already live on the highest floors.
Refusing to Be Optimized Out of Existence
There is another version of the future, still fragile, still struggling to find its voice. It doesn’t reject science or longevity or better medicine; it rejects the idea that these things must be allocated according to “societal ROI.” It insists that human worth is not a spreadsheet cell. It demands that policies about aging, health, housing, and genomics be debated in the open, not smuggled in under the banner of “innovation” and “efficiency.”
Defending that future means asking uncomfortable questions: Who funds this research? Who sits on the ethics boards? Who gets to decide what “productive” means? How do we protect the sick, old, disabled, and “unoptimized” not as objects of charity, but as citizens with equal claim to the technologies their taxes, data, and labor helped build?
It might mean drawing hard lines around some uses of genetic engineering, outlawing quasi-eugenic policies even when they’re dressed in neutral language. It might mean rethinking ownership of key medical breakthroughs, treating them as global commons rather than private property. It certainly means refusing to let “innovation” become a synonym for “whatever makes rich people live longer.”
Above all, it requires something profoundly unfashionable in certain circles: a belief that fragility, dependence, and unproductivity are not bugs to be scrubbed from the human condition, but features of a life lived in community with others. That a society is not great because it engineers a class of immortal elites, but because it cares for those who can no longer code, ship, disrupt, or optimize.
The next time you hear a billionaire talk dreamily about beating death, listen closely for what is left unsaid. In the silence between the applause lines, you may hear the faint rustle of a future being drafted without you—a future that expects you to accept your scheduled exit so that someone more “valuable” can have your seat.
We don’t have to accept that bargain. But to refuse it, we first have to see it for what it is.
FAQ
Are tech billionaires really trying to become immortal?
Most are not talking about literal immortality, but about radically extending healthy lifespan—adding decades of vitality, delaying or preventing age-related decline, and potentially pushing human life expectancy well beyond current limits. However, the rhetoric and investment flows around “defeating aging” often slide into a de facto immortality project for those who can afford it.
Isn’t longevity research good for everyone in the long run?
It can be. Many breakthroughs funded by wealthy individuals and companies may eventually help broad populations. The concern is not the research itself, but who controls it, who gets access first, and whether it deepens inequality by creating a long-lived elite while others are left behind with ordinary lifespans and shrinking support.
How does this connect to eugenics?
Eugenics is about ranking lives and guiding reproduction or survival according to perceived “fitness.” When advanced medicine, genetic tools, and public policy begin to favor certain groups—those who are young, healthy, productive, or affluent—while quietly sidelining the sick, old, disabled, or poor, we drift toward a new, data-driven form of eugenics, even if no one uses the word.
What role do housing and “smart cities” play in this vision?
Some high-tech housing projects and “innovation cities” appear to be designed primarily for long-lived, highly productive residents. In practice, this can mean zoning and planning that excludes or externalizes the elderly poor, chronically ill, and others who don’t fit the “innovation ecosystem,” creating physical spaces that mirror a stratified, optimized society.
Can ordinary people influence these decisions?
Yes, but only if the issues are brought into public view. Pressure on lawmakers, public funding priorities, transparency in research agendas, stronger bioethics oversight, and broad democratic debate can all shape how longevity and genetic technologies are used. The first step is refusing to treat these choices as purely technical or private—and insisting they are political, moral questions we all have a right to answer.
